Mechanisms of failure of chimeric antigen receptor T-cell therapy-Reference-Cited by-同舟云学术

Mechanisms of failure of chimeric antigen receptor T-cell therapy

Published:2019-11 Issue:6 Volume:26 Page:427-433
ISSN:1065-6251
Container-title:Current Opinion in Hematology
language:en
Short-container-title:Current Opinion in Hematology

Author:

Li Xiaoqing,Chen Weihong

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Hematology

Reference43 articles.

1. Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial

2. Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma

3. Updated safety and long term clinical outcomes in TRANSCEND NHL 001, pivotal trial of lisocabtagene maraleucel (JCAR017) in R/R aggressive NHL.

4. 4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors

5. Targeting a CAR to the TRAC locus with CRISPR/Cas9 enhances tumour rejection

Cited by 33 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Targeting endothelial cell anergy to improve CAR T cell therapy for solid tumors;Biochimica et Biophysica Acta (BBA) - Reviews on Cancer;2024-09

2. Prolonged Responses in Central Nervous System Relapsed Diffuse Large B-Cell Lymphoma After Chimeric Antigen Receptor T-Cell Therapy Using Targeted Treatments;Cureus;2024-08-06

3. Targeting Other Promising Cell Surface Receptors;Precision Cancer Therapies vol 2 ‐ Immunologic Approaches for the Treatment of Lymphoid Malignancies ‐ From Concept to Practice;2024-02-21

4. Quartic CAR-T Cell Bridging to Twice Allo-HSCT Therapy in a Patient with Acute Lymphoblastic Leukemia;Transfusion Medicine and Hemotherapy;2023-08-22

5. Best Practices and Considerations for Clinical Pharmacology and Pharmacometric Aspects for Optimal Development of CAR‐T and TCR‐T Cell Therapies: An Industry Perspective;Clinical Pharmacology & Therapeutics;2023-07-26